Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Top Ranked Growth Stocks to Buy for May 4th

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, May 4th:

    United Therapeutics (UTHR) Q1 Earnings Rise, Sales Drop Q/Q

    United Therapeutics' (UTHR) earnings per share rise in the first quarter. Sales drop sequentially due to unfavorable timing of distributor orders. Shares sink almost 7%.

      Top Ranked Growth Stocks to Buy for May 2nd

      Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, May 2nd:

        Top Ranked Growth Stocks to Buy for April 30th

        Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 30th:

          Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

          The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.

            Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up

            Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.

              Kinjel Shah headshot

              Eli Lilly (LLY) Tops Q1 Earnings & Sales, Ups 2018 View

              Eli Lilly (LLY) beat estimates for both earnings and sales in Q1 and raised the guidance for 2018. Shares declined in pre-market trading.

                Is SPDR S&P Pharmaceuticals ETF (XPH) a Hot ETF Right Now?

                Smart Beta ETF report for XPH

                  Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN

                  Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.

                    Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

                    Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                      Top Ranked Growth Stocks to Buy for April 20th

                      Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 20th:

                        Amgen's Aimovig Reduces Episodic Migraine in 30% Patients

                        Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.

                          5 Drug Stocks Poised to Surpass on Earnings This Quarter

                          The outlook for the upcoming first-quarter results looks bright.

                            Merck's Keytruda Betters Survival in Lung Cancer Combo Study

                            Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.

                              Celldex's Phase II Breast Cancer Study Fails, Shares Plunge

                              Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.

                                Merck's Keytruda Reduces Death Risk in Melanoma Patients

                                Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.

                                  AbbVie's RA Candidate Meets Primary Endpoints in Phase III

                                  AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.

                                    vTv Therapeutics Crashes on Alzheimer's Drug Study Failure

                                    vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.

                                      Merck's Keytruda Offers Survival Benefit in Lung Cancer Study

                                      Merck's (MRK) phase III study showed that Keytruda monotherapy led to significantly improved overall survival (OS) as a first-line therapy in certain lung cancer patients.

                                        Kinjel Shah headshot

                                        Novartis and Other Drug Stocks With FDA Catalysts in April

                                        With just a quarter gone by this year, the FDA has already granted approval to six new treatments.

                                          Top Ranked Growth Stocks to Buy for April 10th

                                          Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 10th:

                                            Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study

                                            A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.

                                              FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus

                                              The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.

                                                Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year

                                                ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.

                                                  FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy

                                                  Bristol-Myers' (BMY) filing for Opdivo in combination with Yervoy gains acceptance from the FDA for treating metastatic colorectal cancer. A response is expected in July, 2018.